Practical notes for the evaluation of malignancy in digestive endocrine tumors;Évaluation de la malignité dans les tumeurs endocrines digestives: Recommandations pratiques

Annales de Pathologie

Volumn 25, Issue 6, 2005, Pages 487-498

  Rindi, Guido ^a   Couvelard, Anne ^b   Scoazec, Jean Yves ^c   Bordi, Cesare ^a  

^a UNIVERSITY OF PARMA   (Italy)

^b BEAUJON HOSPITAL   (France)

^c EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Ki67; Poorly differentiated endocrine carcinoma; Prognosis; Well differentiated endocrine carcinoma; Who classification

Indexed keywords

GONADOTROPIN; KI 67 ANTIGEN;

CANCER CLASSIFICATION; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DIGESTIVE SYSTEM TUMOR; ENDOCRINE TUMOR; EVOLUTION; GENETICS; HISTOLOGY; INTESTINE; MALIGNANT NEOPLASTIC DISEASE; MIDGUT; PROGNOSIS; REVIEW; VASCULARIZATION; CLASSIFICATION; GASTROINTESTINAL TUMOR; HUMAN; PANCREAS TUMOR; PATHOLOGY;

DIAGNOSIS, DIFFERENTIAL; DIGESTIVE SYSTEM NEOPLASMS; GASTROINTESTINAL NEOPLASMS; HUMANS; PANCREATIC NEOPLASMS; PROGNOSIS;

EID: 33646359205     PISSN: 02426498     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0242-6498(05)86162-0     Document Type: Short Survey

References (47)

1. Rindi G, Leiter AB, Kopin AS, Bordi C, Solcia E. The "normal" endocrine cell of the gut : changing concepts and new evidences. Ann N Y Acad Sci 2004 ; 1014 : 1-12.
2. Rindi G, Bordi C. Aetiology, molecular pathogenesis and genetics. Best Pract Res Clin Gastroenterol 2005 ; 19 : 519-34.
3. Terris B. Tumeurs endocrines du pancréas : classification, facteurs pronostiques cliniques et moléculaires. Ann Pathol 2002 ; 22 : 367-74.
4. Solcia E, Klöppel G, Sobin LH. Histological typing of endocrine tumours. Springer-Verlag, New York; 2000.
5. Capella C, Heitz PU, Höfler H, Solcia E, Klöppel G. Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Arch 1995 ; 425 : 547-60.
6. Soga J, Tazawa K. Pathologic analysis of carcinoids. Histologic reevaluation of 62 cases. Cancer 1971 ; 28 : 990-8.
7. Rossi G, Valli R, Bertolini F, Sighinolfi P, Losi L, Cavazza A et al. Does mesoappendix infiltration predict a worse prognosis in incidental neuroendocrine tumors of the appendix? A clinicopathologic and immunohistochemical study of 15 cases. Am J Clin Pathol 2003 ; 120 : 706-11.
8. Plockinger U, Rindi G, Arnold R, Eriksson B, Krenning EP, de Herder WW et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 2004 ; 80 : 394-424.
9. Öberg K. State of the art and future prospects in the management of neuroendocrine tumors. Quart J Nucl Med 2000 ; 44 : 3-12.
10. Wiedenmann B, Jensen RT, Mignon M, Modlin CI, Skogseid B, Doherty D et al. Preoperative diagnosis and surgical management of neuroendocrine gastroenteropancreatic tumors : general recommendations by a consensus workshop. World J Surg 1998 ; 22 : 309-18.
11. Reubi JC, Kappeler A, Waser B, Laissue J, Hipkin RW, Schonbrunn A. Immunohistochemical localization of somatostatin receptor sst2A in human tumors. Am J Pathol 1998 ; 153 : 233-45.
12. Oberg K, Kvols L, Caplin M, Delle Fave G, de Herder W, Rindi G et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004; 15 : 966-73.
13. Canavese G, Azzoni C, Pizzi S, Corleto VD, Pasquali C, Davoli C et al. p27 : A potential main inhibitor of cell proliferation in digestive endocrine tumors but not a marker of benign behavior. Hum Pathol 2001 ; 32 : 1094-101.
14. La Rosa S, Sessa F, Capella C, Riva C, Leone BE, Klersy C et al. Prognostic criteria in nonfunctioning pancreatic endocrine tumours. Virchows Arch 1996 ; 429 : 323-33.
15. Furlan D, Bernasconi B, Uccella S, Cerutti R, Carnevali I, Capella C. Allelotypes and fluorescence in situ hybridization profiles of poorly differentiated endocrine carcinomas of different sites. Clin Cancer Res 2005 ; 11 : 1765-75.
16. Furlan D, Cerutti R, Uccella S, La Rosa S, Rigoli E, Genasetti A et al. Different molecular profiles characterize well-differentiated endocrine tumors and poorly differentiated endocrine carcinomas of the gastroenteropancreatic tract. Clin Cancer Res 2004 ; 10 : 947-57.
17. Pizzi S, Azzoni C, Bassi D, Bottarelli L, Milione M, Bordi C. Genetic alterations in poorly differentiated endocrine carcinomas of the gastrointestinal tract. Cancer 2003 ; 98 : 1273-82.
18. Crafa P, Milione M, Azzoni C, Pilato FP, Pizzi S, Bordi C. Pleomorph poorly differentiated endocrine carcinoma of the rectum. Virchows Arch 2003 ; 442 : 605-10.
19. Wick MR, Ritter JH. Neuroendocrine neoplasms : evolving concepts and terminology. Curr Diagn Pathol 2002 ; 8 : 102-12.
20. Hervieu V, Scoazec JY. Les tumeurs mixtes endocrines. Ann Pathol 2006 ; 26 : 511-28.
21. Bordi C, D'Adda T, Azzoni C, Canavese G, Brandi ML. Gastrointestinal endocrine tumors : Recent developments. Endocr Pathol 1998 ; 9 : 99-115.
22. Rossi G, Bertolini F, Sartori G, Bigiani N, Cavazza A, Foroni M et al. Primary mixed adenocarcinoma and small cell carcinoma of the appendix : a clinicopathologic, immunohistochemical, and molecular study of a hitherto unreported tumor. Am J Surg Pathol 2004 ; 28 : 1233-9.
23. Ubiali A, Benetti A, Papotti M, Villanacci V, Rindi G. Genetic alterations in poorly differentiated endocrine colon carcinomas developing in tubulovillous adenomas : a report of two cases. Virchows Arch 2001 ; 439 : 776-81.
24. Vortmeyer AO, Lubensky IA, Merino MJ, Wang CY, Pham T, Furth EE et al. Concordance of genetic alterations in poorly differentiated colorectal neuroendocrine carcinomas and associated adenocarcinomas. J Natl Cancer Inst 1997 ; 89 : 1448-53.
25. Pelosi G, Bresaola E, Bogina G, Pasini F, Rodella S, Castelli P et al. Endocrine tumors of the pancreas: Ki-67 immunoreactivity on paraffin sections is an independent predictor for malignancy : a comparative study with proliferating-cell nuclear antigen and progesterone receptor protein immunostaining, mitotic index, and other clinicopathologic variables. Hum Pathol 1996 ; 27 : 1124-34.
26. Hochwald SN, Zee S, Conlon KC, Colleoni R, Louie O, Brennan MF et al. Prognostic factors in pancreatic endocrine neoplasms : an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol 2002 ; 20 : 2633-42.
27. Rindi G, Azzoni C, La Rosa S, Klersy C, Paolotti D, Rappel S et al. ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach : Prognostic evaluation by pathological analysis. Gastroenterology 1999 ; 116 : 532-42.
28. Deshpande V, Fernandez-del Castillo C, Muzikansky A, Deshpande A, Zukerberg L, Warshaw AL et al. Cytokeratin 19 is a powerful predictor of survival in pancreatic endocrine tumors. Am J Surg Pathol 2004 ; 28 : 1145-53.
29. Chaudhry A, Öberg K, Wilander E. A study of biological behavior based on the expression of a proliferating antigen in neuroendocrine tumors of the digestive system. Tumor Biol 1992 ; 13 : 27-35.
30. Heitz PU, Kasper M, Klöppel G, Polak JM, Vaitukaitis JL. Glycoprotein-hormone alpha-chain production by pancreatic endocrine tumors : a specific marker for malignancy. Immunocytochemical analysis of tumors of 155 patients. Cancer 1983 ; 51 : 277-82.
31. Bordi C, Pilato FP, D'Adda T. Comparative study of seven neuroendocrine markers in pancreatic endocrine tumours. Virchows Arch A 1988 ; 413 : 387-98.
32. Donow C, Baisch H, Heitz PU, Klöppel G. Nuclear DNA content in 27 pancreatic endocrine tumours. Correlation with malignancy, survival and expression of glycoprotein hormone alpha chain. Virchows Arch (Path Anat) 1991 ; 419 : 463-8.
33. Graeme-Cook F, Nardi G, Compton C. Immunocytochemical staining for human chorionic gonadotropin subunits does not predict malignancy in insulinomas. Am J Clin Pathol 1990 ; 93 : 273-6.
34. Bordi C, D'Adda T, Azzoni C, Pilato FP, Caruana P. Hypergastrinemia and gastric enterochromaffin-like cells. Am J Surg Pathol 1995 ; 19 (suppl 1) : S8-S19.
35. Bordi C, D'Adda T, Azzoni C, Ferraro G. Pathogenesis of ECL cell tumors in humans. Yale J Biol Med 1998 ; 71 : 273-84.
36. Carlinfante G, Lampugnani R, Azzoni C, Aprile MR, Brandi ML, Bordi C. Expression of the α- and β-subunits of human chorionic gonadotropin by subsets of parathyroid cells in states of hyperparathyroidism. J Pathol 1998 ; 185 : 389-93.
37. Fukayama M, Hayashi Y, Shiozawa Y, Okabe S, Koike M. Human chorionic gonadotropin alpha-subunit in rectal carcinoids. Its mode of presence and the change of granule morphology. Am J Pathol 1989 ; 135 : 1065-72.
38. Marion-Audibert AM, Barel C, Gouysse G, Dumortier J, Pilleul F, Pourreyron C et al. Low microvessel density is an unfavorable histoprognostic factor in pancreatic endocrine tumors. Gastroenterology 2003 ; 125 : 1094-104.
39. Couvelard A, O'Toole D, Turley H, Leek R, Sauvanet A, Degott C et al. Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours : negative correlation of microvascular density and VEGF expression with tumour progression. Br J Cancer 2005 ; 92 : 94-101.
40. Grabowski P, Griss S, Arnold CN, Horsch D, Goke R, Arnold R et al. Nuclear survivin is a powerful novel prognostic marker in gastroenteropancreatic neuroendocrine tumor disease. Neuroendocrinology 2005 ; 81 : 1-9.
41. Furukawa M, Raffeld M, Mateo C, Sakamoto A, Moody TW, Ito T et al. Increased expression of insulin-like growth factor I and/or its receptor in gastrinomas is associated with low curability, increased growth, and development of metastases. Clin Cancer Res 2005 ; 11 : 3233-42.
42. Goto A, Niki T, Terado Y, Fukushima J, Fukayama M. Prevalence of CD99 protein expression in pancreatic endocrine tumours (PETs). Histopathology 2004 ; 45 : 384-92.
43. Rigaud G, Missiaglia E, Moore PS, Zamboni G, Falconi M, Talamini G et al. High resolution allelotype of nonfunctional pancreatic endocrine tumors : Identification of two molecular subgroups with clinical implications. Cancer Res 2001 ; 61 : 285-92.
44. Rindi G, Villanacci V, Ubiali A, Scarpa A. Endocrine tumors of the digestive tract and pancreas : histogenesis, diagnosis and molecular basis. Expert Rev Mol Diagn 2001 ; 1 : 323-33.
45. Pizzi S, D'Adda T, Azzoni C, Rindi G, Grigolato P, Pasquali C et al. Malignancy-associated allelic losses on the X-chromosome in foregut but not in midgut endocrine tumours. J Pathol 2002 ; 196 : 401-7.
46. Pizzi S, Azzoni C, Bottarelli L, Campanini N, D'Adda T, Pasquali C et al. RASSF1A promoter methylation and 3p21.3 loss of heterozygosity are features of foregut, but not midgut and hindgut, malignant endocrine tumours. J Pathol 2005 ; 206 : 409-16.
47. Leotlela PD, Jauch A, Holtgreve-Grez H, Thakker RV. Genetics of neuroendocrine and carcinoid tumours. Endocr Relat Cancer 2003 ; 10 : 437-50.